Published February 2011 | Version public
Journal Article

Clinical Developments in Nanotechnology for Cancer Therapy

  • 1. ROR icon Calando Pharmaceuticals (United States)
  • 2. ROR icon California Institute of Technology

Abstract

Nanoparticle approaches to drug delivery for cancer offer exciting and potentially "game-changing" ways to improve patient care and quality of life in numerous ways, such as reducing off-target toxicities by more selectively directing drug molecules to intracellular targets of cancer cells. Here, we focus on technologies being investigated clinically and discuss numerous types of therapeutic molecules that have been incorporated within nanostructured entities such as nanoparticles. The impacts of nanostructured therapeutics on efficacy and safety, including parameters like pharmacokinetics and biodistribution, are described for several drug molecules. Additionally, we discuss recent advances in the understanding of ligand-based targeting of nanoparticles, such as on receptor avidity and selectivity.

Additional Information

© 2010 Springer Science+Business Media, LLC. Received: 10 March 2010; Accepted: 19 May 2010; Published online: 12 June 2010.

Additional details

Identifiers

Eprint ID
22447
Resolver ID
CaltechAUTHORS:20110223-093924933

Dates

Created
2011-02-24
Created from EPrint's datestamp field
Updated
2021-11-09
Created from EPrint's last_modified field